Abstract
Genetic polymorphisms that influence smooth muscle cell contraction and relaxation may affect the response to anti-hypertensive therapy. Our finding of lower blood pressure (BP) in the setting of treatment for hypertension, particularly with beta-blockade, in Caucasian KCNMB1-E65K-carriers in two community cohorts has implications for personalization of therapy in hypertension.